

What Should Directors Be Asking? Antitrust in the Boardroom

A photograph of a modern building with a curved, glass-and-metal facade, viewed from a low angle looking up.

PODCAST | 1 MIN READ

August 3, 2026

Competition law isn't just for antitrust lawyers anymore—it's increasingly a boardroom issue. What questions should directors be asking to ensure their companies are identifying and managing competition risk before it becomes a crisis?

Managing partner [Jeny Maier](#) and Anora Wang speak with Julie Goshorn, whose career spans the DOJ, FTC, private practice at Arnold & Porter, and global in-house leadership at Visa, about why corporate boards should view antitrust as an enterprise risk alongside cybersecurity, financial controls, and compliance. Listen to this episode to learn about the board's oversight role, lessons from recent Delaware fiduciary duty cases, and the practical questions every director should be asking to help protect long-term enterprise value.


Watch below or on the [Our Curious Amalgam](#) website.

#389 What Should Directors Be Asking? Antitrust in the Boardroom

ABA Antitrust Law Section



Related People



Jeny M. Maier

Related Services

Antitrust

To subscribe to our publications, [click here](#).

Featured Insights

- 30th Annual IBA Competition Conference
SPEAKING ENGAGEMENT ANTITRUST
- Axinn Represents Modular in \$4 Billion Acquisition by Qualcomm

DEALS & CASES ANTITRUST

- Will New DOJ Timing Agreement Deliver Faster Merger Clearances?
AXINN VIEWPOINTS ANTITRUST
- Why U.S. Regulators Are Cracking Down on Private Equity Investments in the Healthcare Sector
BYLINE ARTICLES ANTITRUST
- Women Leaders in Life Sciences Law
SPEAKING ENGAGEMENT LITIGATION & TRIALS
- American Bar Association: Inside Antitrust Enforcement—Former Government Perspectives
WEBINAR ANTITRUST
- What's the Skinny on SCOTUS' Skinny Label Decision?
WEBINAR INTELLECTUAL PROPERTY
- National Bar Association Corporate Counsel Leadership Summit
SPEAKING ENGAGEMENT ANTITRUST
- FTC Prescribes Lower Out-of-Pocket Insulin Costs in Settlement with Caremark
AXINN VIEWPOINTS ANTITRUST
- The FTC's Record \$12 Million HSR Penalty: Deal Structuring, Avoidance, and the Line Between Them
AXINN VIEWPOINTS ANTITRUST